Compare Stocks: XTLB, AKTX, CMMB, and ALVR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$11.47 +5.8%	$9.60	$3.02 ▼ $49.60	$21.10M	1.43	78,644 shs	108,165 shs
ALVR AlloVir	$3.94 +1.0%	$4.14	$7.96 ▼ $24.15	$19.87M	0.63	15,685 shs	39,986 shs
CMMB Chemomab Therapeutics	$2.71 -4.2%	$1.94	$1.35 ▼ $3.58	$20.50M	0.76	103,851 shs	118,508 shs
XTLB XTL Biopharmaceuticals	$2.46 -1.8%	$2.77	$2.01 ▼ $10.28	$5.51M	1.38	12,090 shs	1,829 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	+5.81%	+7.20%	+52.93%	-23.89%	-56.22%
ALVR AlloVir	+1.03%	-3.90%	-8.80%	-11.26%	-1.50%
CMMB Chemomab Therapeutics	-4.24%	0.00%	+54.86%	+53.11%	-10.26%
XTLB XTL Biopharmaceuticals	-1.80%	-0.61%	-13.86%	+19.17%	-87.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$11.47 +5.8%	$9.60	$3.02 ▼ $49.60	$21.10M	1.43	78,644 shs	108,165 shs
ALVR AlloVir	$3.94 +1.0%	$4.14	$7.96 ▼ $24.15	$19.87M	0.63	15,685 shs	39,986 shs
CMMB Chemomab Therapeutics	$2.71 -4.2%	$1.94	$1.35 ▼ $3.58	$20.50M	0.76	103,851 shs	118,508 shs
XTLB XTL Biopharmaceuticals	$2.46 -1.8%	$2.77	$2.01 ▼ $10.28	$5.51M	1.38	12,090 shs	1,829 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	+5.81%	+7.20%	+52.93%	-23.89%	-56.22%
ALVR AlloVir	+1.03%	-3.90%	-8.80%	-11.26%	-1.50%
CMMB Chemomab Therapeutics	-4.24%	0.00%	+54.86%	+53.11%	-10.26%
XTLB XTL Biopharmaceuticals	-1.80%	-0.61%	-13.86%	+19.17%	-87.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	2.50	Moderate Buy	$32.33	181.89% Upside
ALVR AlloVir	0.00	N/A	N/A	N/A
CMMB Chemomab Therapeutics	1.50	Reduce	N/A	N/A
XTLB XTL Biopharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XTLB, AKTX, CMMB, and ALVR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/5/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/20/2026	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
7/6/2026	AKTX Akari Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/6/2026	XTLB XTL Biopharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$9.55 per share	N/A
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$1.20 per share	N/A
XTLB XTL Biopharmaceuticals	$450K	12.00	N/A	N/A	($0.12) per share	-20.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$17.30M	N/A	N/A	N/A	N/A	N/A	-147.45%	-74.70%	N/A
ALVR AlloVir	-$190.42M	-$20.23	N/A	N/A	N/A	N/A	-71.03%	-61.27%	N/A
CMMB Chemomab Therapeutics	-$8.99M	-$2.13	N/A	N/A	N/A	N/A	-92.14%	-82.05%	11/6/2026 (Estimated)
XTLB XTL Biopharmaceuticals	-$6.97M	-$0.64	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest XTLB, AKTX, CMMB, and ALVR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/20/2026	Q2 2026	CMMB Chemomab Therapeutics	-$0.15	-$0.27	-$0.12	-$0.24	N/A	N/A
6/30/2026	Q4 2025	XTLB XTL Biopharmaceuticals	N/A	-$0.10	N/A	-$0.10	N/A	($0.26) million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.60	0.60
ALVR AlloVir	N/A	86.78	86.78
CMMB Chemomab Therapeutics	N/A	6.41	6.41
XTLB XTL Biopharmaceuticals	N/A	0.40	0.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
ALVR AlloVir	66.05%
CMMB Chemomab Therapeutics	46.05%
XTLB XTL Biopharmaceuticals	4.40%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	32.20%
ALVR AlloVir	32.07%
CMMB Chemomab Therapeutics	11.91%
XTLB XTL Biopharmaceuticals	29.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	1.95 million	1.32 million	Not Optionable
ALVR AlloVir	110	5.04 million	3.43 million	No Data
CMMB Chemomab Therapeutics	20	7.25 million	6.38 million	Not Optionable
XTLB XTL Biopharmaceuticals	N/A	2.20 million	1.57 million	Not Optionable

XTLB, AKTX, CMMB, and ALVR Headlines

Recent News About These Companies

XTL Biopharmaceuticals Ltd. Sponsored ADR

July 8, 2026 | cnn.com

XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) After-Hours

July 1, 2026 | nasdaq.com

XTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology Platform

June 30, 2026 | quiverquant.comQ

XTL Completed the Acquisition of Psyga Bio Ltd.

June 30, 2026 | globenewswire.com

XTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026

June 23, 2026 | tipranks.com

XTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Staff Delist Determination from Nasdaq

May 23, 2026 | finanznachrichten.de

XTL Announces Receipt of Staff Delist Determination from Nasdaq

May 22, 2026 | globenewswire.com

XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise

May 15, 2026 | tipranks.com

XTL Biopharmaceuticals Ltd ADR XTLB

May 14, 2026 | morningstar.comM

XTL Biopharmaceuticals Delays 20-F Amid Subsidiary Liquidation

May 3, 2026 | theglobeandmail.com

XTL Biopharmaceuticals Ltd.

May 1, 2026 | marketwatch.com

Washington Just Opened the Door to Psychedelic Medicine; This Microcap Already Has a Key

May 1, 2026 | theglobeandmail.com

XTLB stock surges 50%, breaches 200-DMA for first time in over 3 months – here’s what the acquisition of Psyga Bio brings to the table

May 1, 2026 | msn.com

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and ...

April 29, 2026 | markets.businessinsider.com

XTL Biopharmaceuticals (XTLB) acquisition of Psyga Bio targets psychedelic biotech growth

April 29, 2026 | msn.com

XTL Biopharmaceuticals soars after all-stock Psyga Bio acquisition announcement

April 29, 2026 | quiverquant.comQ

XTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug Pipeline

April 29, 2026 | tipranks.com

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

April 29, 2026 | globenewswire.com

XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Announces ADS Ratio Change

March 21, 2026 | finanznachrichten.de

XTL Biopharmaceuticals Announces ADS Ratio Change

March 20, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB, AKTX, CMMB, and ALVR Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$11.54 +0.70 (+6.49%)

As of 09/4/2026 03:57 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AlloVir NASDAQ:ALVR

$3.94 +0.04 (+1.03%)

As of 09/3/2026

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Chemomab Therapeutics NASDAQ:CMMB

$2.71 -0.12 (-4.24%)

As of 09/4/2026 04:00 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

XTL Biopharmaceuticals NASDAQ:XTLB

$2.46 -0.05 (-1.80%)

As of 09/4/2026 03:57 PM Eastern

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XTLB, AKTX, CMMB, and ALVR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XTLB, AKTX, CMMB, and ALVR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XTLB, AKTX, CMMB, and ALVR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB, AKTX, CMMB, and ALVR Company Descriptions

Akari Therapeutics NASDAQ:AKTX

AlloVir NASDAQ:ALVR

Chemomab Therapeutics NASDAQ:CMMB

XTL Biopharmaceuticals NASDAQ:XTLB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XTLB, AKTX, CMMB, and ALVR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XTLB, AKTX, CMMB, and ALVR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XTLB, AKTX, CMMB, and ALVR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB, AKTX, CMMB, and ALVR Company Descriptions

Akari Therapeutics NASDAQ:AKTX

AlloVir NASDAQ:ALVR

Chemomab Therapeutics NASDAQ:CMMB

XTL Biopharmaceuticals NASDAQ:XTLB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools